Eliminating viral hepatitis C in Belgium: the micro-elimination approach.
Adolescent
Adult
Antiviral Agents
/ therapeutic use
Belgium
Child
Child, Preschool
Disease Eradication
/ methods
Health Policy
Hemophilia A
/ complications
Hepatitis C
/ complications
Homosexuality, Male
Humans
Infant
Male
Models, Theoretical
Prisoners
Registries
Substance-Related Disorders
/ complications
Transplants
Young Adult
Belgium
Disease elimination
Health policy
Hepatitis C
Treatment
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
27 Feb 2020
27 Feb 2020
Historique:
received:
03
07
2019
accepted:
17
02
2020
entrez:
29
2
2020
pubmed:
29
2
2020
medline:
6
5
2020
Statut:
epublish
Résumé
Hepatitis C virus is one of the leading causes of chronic liver disease and liver-related deaths worldwide. The estimated prevalence of chronic hepatitis C viral infection among the general Belgian population was 0.57% (n = 64,000) in 2015. Although Belgium has had a 'Hepatitis C Plan' since 2014, elimination efforts are unclear. This study employs the best available data and modelling estimates to define the burden of hepatitis C viral infection among key subgroups in Belgium, identify information gaps and propose potential approaches to screening, linkage to care and treatment, and cure. We examined the peer-reviewed and grey literature since 2012 for data on the prevalence of hepatitis C viral infection in Belgium in key subgroups identified by national experts and in the literature. Ultimately, this research is primarily based on data provided by the key stakeholders themselves due to a lack of reliable data in the literature. Based on this, we modelled the treatment rates required to reach elimination of hepatitis C in several subgroups. Eleven potential subgroups were identified. There were no data available for two subgroups: generational cohorts and men who have sex with men. In six subgroups, fewer than 3000 people were reported or estimated to have hepatitis C infection. Migrants and people who inject drugs were the most affected subgroups, and children were the least affected subgroup. Only two subgroups are on target to achieve elimination by 2030: patients living with haemophilia and transplant recipients. Removing Belgian treatment reimbursement restrictions in January 2019 was a big step towards eliminating HCV. In addition, increasing surveillance, including with a national registry, treatment prescription by other health-care providers and availability of treatment in local pharmacies are central to improving the current situation and getting on track to reach the 2030 WHO hepatitis C elimination targets in Belgium.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis C virus is one of the leading causes of chronic liver disease and liver-related deaths worldwide. The estimated prevalence of chronic hepatitis C viral infection among the general Belgian population was 0.57% (n = 64,000) in 2015. Although Belgium has had a 'Hepatitis C Plan' since 2014, elimination efforts are unclear. This study employs the best available data and modelling estimates to define the burden of hepatitis C viral infection among key subgroups in Belgium, identify information gaps and propose potential approaches to screening, linkage to care and treatment, and cure.
METHODS
METHODS
We examined the peer-reviewed and grey literature since 2012 for data on the prevalence of hepatitis C viral infection in Belgium in key subgroups identified by national experts and in the literature. Ultimately, this research is primarily based on data provided by the key stakeholders themselves due to a lack of reliable data in the literature. Based on this, we modelled the treatment rates required to reach elimination of hepatitis C in several subgroups.
RESULTS
RESULTS
Eleven potential subgroups were identified. There were no data available for two subgroups: generational cohorts and men who have sex with men. In six subgroups, fewer than 3000 people were reported or estimated to have hepatitis C infection. Migrants and people who inject drugs were the most affected subgroups, and children were the least affected subgroup. Only two subgroups are on target to achieve elimination by 2030: patients living with haemophilia and transplant recipients.
CONCLUSIONS
CONCLUSIONS
Removing Belgian treatment reimbursement restrictions in January 2019 was a big step towards eliminating HCV. In addition, increasing surveillance, including with a national registry, treatment prescription by other health-care providers and availability of treatment in local pharmacies are central to improving the current situation and getting on track to reach the 2030 WHO hepatitis C elimination targets in Belgium.
Identifiants
pubmed: 32106819
doi: 10.1186/s12879-020-4898-y
pii: 10.1186/s12879-020-4898-y
pmc: PMC7045456
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
181Subventions
Organisme : MSD
ID : n/a
Références
Value Health. 2017 Mar;20(3):310-319
pubmed: 28292475
Int J Drug Policy. 2007 Oct;18(5):397-405
pubmed: 17854728
Clin J Am Soc Nephrol. 2017 Feb 7;12(2):287-297
pubmed: 27908905
World J Gastroenterol. 2013 Nov 28;19(44):7880-8
pubmed: 24307782
Gastroenterol Hepatol (N Y). 2017 Dec;13(12 Suppl 5):1-24
pubmed: 29950953
Am J Nephrol. 2013;38(5):405-12
pubmed: 24192505
World J Gastroenterol. 2015 Oct 14;21(38):10783-9
pubmed: 26478670
Lancet Gastroenterol Hepatol. 2017 May;2(5):325-336
pubmed: 28397696
Clin Infect Dis. 2017 Apr 1;64(7):860-869
pubmed: 28362947
Lancet Infect Dis. 2016 Jun;16(6):685-697
pubmed: 26907736
Addiction. 2017 Feb;112(2):250-258
pubmed: 27633487
Lancet. 2010 Jul 24;376(9737):285-301
pubmed: 20650522
Eur J Gastroenterol Hepatol. 2006 Feb;18(2):159-66
pubmed: 16394797
J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):585-93
pubmed: 25763786
BMC Infect Dis. 2018 Jan 16;18(1):42
pubmed: 29338702
J Hepatol. 2017 Dec;67(6):1168-1176
pubmed: 28842296
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
J Hepatol. 2018 Aug;69(2):461-511
pubmed: 29650333
Lancet. 2016 Sep 10;388(10049):1089-1102
pubmed: 27427453
J Hepatol. 2014 Jan;60(1):39-45
pubmed: 23978717
Drug Alcohol Depend. 2017 Aug 1;177:214-220
pubmed: 28618285
Lancet Infect Dis. 2016 Jul;16(7):797-808
pubmed: 26922272
Acta Gastroenterol Belg. 2014 Jun;77(2):280-4
pubmed: 25090834
Nephrol Dial Transplant. 1996;11 Suppl 4:36-8
pubmed: 8918750
Acta Clin Belg. 2013 Nov-Dec;68(6):421-6
pubmed: 24635329
Hepatology. 2017 Jun;65(6):1810-1822
pubmed: 28170112
Arch Public Health. 2013 May 03;71(1):10
pubmed: 23642251
J Viral Hepat. 2014 May;21 Suppl 1:34-59
pubmed: 24713005
J Hepatol. 2016 Sep;65(3):524-31
pubmed: 27212241
J Hepatol. 2017 Jan;66(1):153-194
pubmed: 27667367
Kidney Int. 1996 Mar;49(3):889-95
pubmed: 8648934
Addiction. 2018 Mar;113(3):545-563
pubmed: 28891267
J Hepatol. 2017 Feb;66(2):282-287
pubmed: 27650285
J Hepatol. 2015 Aug;63(2):515-22
pubmed: 25962882
J Infect Dis. 2011 Jul 1;204(1):74-83
pubmed: 21628661
J Infect Dis. 2008 Apr 15;197(8):1213-4, author reply 1214-5
pubmed: 18462168
Acta Gastroenterol Belg. 2016 Apr-Jun;79(2):227-32
pubmed: 27382943
J Hepatol. 2018 Mar;68(3):402-411
pubmed: 29080808
J Hepatol. 2017 Oct;67(4):665-666
pubmed: 28760329
Addiction. 2011 Nov;106(11):1978-88
pubmed: 21615585
J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25052
pubmed: 29633562
PLoS One. 2014 Jul 28;9(7):e103345
pubmed: 25068274
World J Gastroenterol. 2016 Jan 28;22(4):1382-92
pubmed: 26819507
J Viral Hepat. 2018 Mar;25(3):236-244
pubmed: 29053912
Lancet. 2015 Jan 10;385(9963):117-71
pubmed: 25530442
Nephrol Dial Transplant. 2004 Apr;19(4):904-9
pubmed: 15031348
Hepatology. 2017 Mar;65(3):777-788
pubmed: 27906468
Euro Surveill. 2010 Sep 30;15(39):19673
pubmed: 20929655
MMWR Recomm Rep. 2012 Aug 17;61(RR-4):1-32
pubmed: 22895429
J Hepatol. 2018 Nov;69(5):1188-1196
pubmed: 29959953
Acta Gastroenterol Belg. 2014 Jun;77(2):277-9
pubmed: 25090833
Kidney Int Suppl. 2008 Apr;(109):S1-99
pubmed: 18382440
J Hepatol. 2018 Oct;69(4):762-764
pubmed: 30049544
Am J Epidemiol. 2008 Nov 15;168(10):1099-109
pubmed: 18849303
Int J Drug Policy. 2017 Sep;47:51-60
pubmed: 28683982
Gastroenterology. 2015 Sep;149(3):649-59
pubmed: 25985734
Kidney Int. 2018 Oct;94(4):663-673
pubmed: 30243313
Liver Int. 2019 Apr;39(4):667-675
pubmed: 30525269
Ann Intern Med. 2012 Feb 21;156(4):263-70
pubmed: 22056542
AIDS. 2017 Jul 17;31(11):1603-1610
pubmed: 28657964
Semin Liver Dis. 2018 Aug;38(3):181-192
pubmed: 29986353
Lancet. 2016 Sep 17;388(10050):1228-48
pubmed: 27427455
Hepatology. 2002 Nov;36(5 Suppl 1):S106-13
pubmed: 12407583
Int J Drug Policy. 2014 Jan;25(1):34-52
pubmed: 23973009
Gastroenterology. 2017 Apr;152(5):1090-1099.e1
pubmed: 28088461
Hematology. 2001;6(2):135-42
pubmed: 27419880
Arch Dis Child. 2017 Jul;102(7):668-671
pubmed: 28473309
Sex Transm Dis. 2011 Feb;38(2):102-4
pubmed: 20706177
Lancet Gastroenterol Hepatol. 2018 Feb;3(2):125-133
pubmed: 28986139
BMC Med. 2017 May 3;15(1):92
pubmed: 28464883
Clin Infect Dis. 2015 Jun 1;60(11):1728-9
pubmed: 25694649